Back to discover
Drug

Galactose

In clinical development
Emerging researchLate-stage developmentRising momentum

Also known as D(+)-Galactose, D-Galactose.

RxNorm4626ChEMBLCHEMBL6067641ATCV04CE01ATCV08DA02UNIIX2RN3Q8DNE
3
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Effects of exercise-targeted hippocampal PDE-4 methylation on synaptic plasticity and spatial learning/memory impairments in D-galactose-induced aging rats.

Research2023-12-05Experimental brain research

Ligand Recognition by the Macrophage Galactose-Type C-Type Lectin: Self or Non-Self?-A Way to Trick the Host's Immune System.

Research2023-12-03International journal of molecular sciences

Macrophages and the Macrophage Activation Markers sCD163 and Mannose Receptor (sMR) in Patients With Wilsons Disease - Associations With Liver Disease Severity and Fibrosis

Clinical trial2022-02-01Completed · ClinicalTrials.gov

Novel Therapies for Resistant Focal Segmental Glomerulosclerosis

Clinical trial2016-07-11Results posted · ClinicalTrials.gov

Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.

Research2015-07-22BMC nephrology

Effect of Oral Galactose on the Level of Focal Sclerosis Permeability Factor and Proteinuria in Children With Steroid Resistant Nephrotic Syndrome: A Pilot Study

Clinical trial2014-09-15Results posted · ClinicalTrials.gov

A Comparison of Direct Peritoneal Resuscitation Plus Conventional Resuscitation Versus Conventional Resuscitation Alone in Patients Undergoing Hepatic Resection for Cancer

Clinical trial2014-05-01Withdrawn · ClinicalTrials.gov

Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)

Clinical trial2009-12-01Terminated · ClinicalTrials.gov

Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)and Chronic Kidney Disease Stage 5

Clinical trial2009-12-01Withdrawn · ClinicalTrials.gov

Diabetic Macular Oedema: Quantification of the Effect of Rising the Intracapillary Osmotic Pressure With Intravenous Galactose on the Retinal Thickness

Clinical trial2007-03-01Terminated · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Galactose
Aliases & brands
D(+)-GalactoseD-Galactose
RxNorm CUI
4626
ChEMBL ID
CHEMBL6067641
ATC codes
V04CE01V08DA02
UNII
X2RN3Q8DNE

Clinical trials

7 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
7
registered trials across all phases
LATEST COMPLETION 2022
4
Late-stage (III+)
3
Completed
4
Discontinued
PHASE DISTRIBUTIONn = 7
Phase 12Phase 21Phase 41Phase N / A3

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Comparison of Direct Peritoneal Resuscitation Plus Conventional Resuscitation Versus Conventional Resuscitation Alone in Patients Undergoing Hepatic Resection for Cancer

WithdrawnPH IVUniversity of Louisville2014

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20152024
Major research themes3
Galactose2Antigen-Presenting Cells1Spatial Learning1
Journals, researchers & institutions
Top journals
  • BMC nephrology1
  • Experimental brain research1
  • International journal of molecular sciences1
Leading researchers
  • Wei C2
  • Gassman J1
  • Gipson DS1
  • Herreshoff E1
  • Jin Y1
  • Li X1
  • Radeva M1
  • Reiser J1
Leading institutions
free-text, unnormalised
  • Albert Einstein College of Medicine1
  • Boston Children's Medical Center1
  • Children's Mercy Hospital1
  • Cleveland Clinic Foundation1
  • Kansas City Veteran's Administration Medical Center1
  • NYU Langone Medical Center1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials